EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022

Christophe Le Terrier, Maxime Bouvier, Auriane Kerbol, Chloé Dell'Acqua, Nara Network members, Patrice Nordmann, Laurent Poirel

European Journal of Clinical Microbiology & Infectious Diseases · 2025-03 · 44 (3) · 571-585

DOI: 10.1007/s10096-024-04994-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, online erschienen am 20.12.2024. Verfasst von Christophe Le Terrier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, Fribour…. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Anti-Bacterial Agents, Pseudomonas, Pseudomonas Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Fribourg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the in-vitro activity of the novel commercially-available drugs, including meropenem-vaborbactam (MEV), ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), imipenem-relebactam (IPR) as well as cefiderocol (FDC), against carbapenem-resistant Pseudomonas spp. (CRP) isolates. All CRP isolates collected at the Swiss National Reference Laboratory (NARA) over the year 2022 ( n = 170) have been included. Most of these isolates ( n = 121) were non-carbapenemase producers. Among the 49 carbapenemase producers, 47 isolates produced metallo-β-lactamases (MBL) including NDM-1 ( n = 11), VIM-like ( n = 28), IMP-like ( n = 7), and both NDM-1 and VIM-2 ( n = 1) and two isolates produced the class A carbapenemase GES-5. Susceptibility testing was determined by broth microdilution method (BMD), or disk diffusion test, and results interpreted following EUCAST guidelines. The susceptibility rates for MEV, CZA, C/T and IPR were found to be 41%, 45%, 59% and 58%, respectively, for the whole set of isolates tested. Among non-carbapenemase producers, susceptibility rates for these β-lactam/β-lactamase inhibitors (BL/BLI) combinations were higher, determined at 55%, 61%, 83%, and 82%, respectively. The overall susceptibility of carbapenemase-producing Pseudomonas spp. to novel BL/BLI was relatively low, while 80% of these isolates demonstrated susceptibility to FDC, with a similar proportion (79%) observed among MBL producers. A total of 10 MBL-producing isolates (6%), mainly NDM-1, were found to exhibit resistance to all drugs tested, with the exception of colistin. FDC exhibited an excellent in-vitro activity against this collection of CRP recovered from Switzerland in 2022, including MBL producers. The new BL/BLI combinations displayed significant activity against non-carbapenemase CRP, with IPR and C/T showing the highest susceptibility rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase InhibitorsAnti-Bacterial AgentsPseudomonasPseudomonas InfectionsCephalosporinsHumansSwitzerlandMicrobial Sensitivity TestsCefiderocolCarbapenemsbeta-LactamasesDrug CombinationsAzabicyclo CompoundsTazobactamBacterial ProteinsCeftazidime

Stichwörter der Autor:innen

AvibactamCarbapenemaseCefiderocolCeftolozaneImipenemMeropenemRelebactamVaborbactamΒ-lactamase

Substanzen

beta-Lactamase InhibitorsAnti-Bacterial AgentsCefiderocolCarbapenemsbeta-LactamasesCephalosporinsDrug Combinationsavibactam, ceftazidime drug combinationAzabicyclo Compoundscarbapenemase

Autor:innen und Institutionen

  • Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, Fribourg, CH-1700, Switzerland.
  • Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
  • Emergency Department, Fribourg Hospitals, Fribourg, Switzerland.
  • Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland.
  • Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, Fribourg, CH-1700, Switzerland. laurent.poirel@unifr.ch.
  • Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland. laurent.poirel@unifr.ch.

Förderung

  • University of Fribourg

Zitieren

APA

Le Terrier, C., Bouvier, M., Kerbol, A., Dell'Acqua, C., Nara Network members, Nordmann, P., & Poirel, L. (2025). In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. European Journal of Clinical Microbiology & Infectious Diseases, 44(3), 571-585. https://doi.org/10.1007/s10096-024-04994-6

Vancouver

Le Terrier C, Bouvier M, Kerbol A, Dell'Acqua C, Nara Network members, Nordmann P, et al. In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. European Journal of Clinical Microbiology & Infectious Diseases. 2025;44(3):571-585. doi:10.1007/s10096-024-04994-6

BibTeX
@article{LeTerrier2025,
  author = {Le Terrier, Christophe and Bouvier, Maxime and Kerbol, Auriane and Dell'Acqua, Chloé and Nara Network members, Nara Network members and Nordmann, Patrice and Poirel, Laurent},
  title = {In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2025},
  volume = {44},
  number = {3},
  pages = {571--585},
  doi = {10.1007/s10096-024-04994-6}
}
Kostenlos starten →